drugset / Trial / NCT00022555

Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma

NCT00022555

Phase 1 Completed 12 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of bryostatin 1 plus vincristine in treating patients who have recurrent or refractory lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bryostatin 1 may help vincristine kill more cancer cells by making them more sensitive to the drug

Timeline

Start
2001-11
Primary completion
2003-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vincristine Small molecule Intravenous
Subject bryostatin 1 Small molecule Intravenous